
CLAIMS


1. Use of the compound BP1.4979, of formula:



,

N-(4-{2-[4-(3-Cyanophenyl)piperazin-1-yl]ethyl}cyclohexyl)-3-methoxypropanamide or a pharmaceutically acceptable salt thereof, or crystalline structures thereof for the manufacture of a medicament for treating restless leg syndrome (RLS) at a dose comprised between 10 and 15 mg B.I.D. (bis in die).

2. Use of the compound BP1.4979, of formula:



,

N-(4-{2-[4-(3-Cyanophenyl)piperazin-1-yl]ethyl}cyclohexyl)-3-methoxypropanamide or a pharmaceutically acceptable salt thereof, or crystalline structures thereof for the manufacture of a medicament for treating binge eating disorder.

3. The use according to claim 2, comprising administering said compound at a dose comprised between 10 and 100 mg B.I.D. (*bis in die*).

4. The use according to claim 2, comprising administering said compound at a dose comprised between 10 and 15 mg B.I.D. (*bis in die*).